X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration is to Utilize CytomX’s Novel Probody® Technology Platform for CD3 Bispecific Targets for the treatment of cancer. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $1,680.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration April 03, 2024
Details:
The clinical candidate is the first PROBODY® T-cell engaging bispecific (TCB) molecule under the alliance between CytomX and Astellas to progress into a GLP toxicology study.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $1,680.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration March 18, 2024
Details:
The collaboration evolves to ongoing research programs, including multiple T-cell engagers. The anti-CTLA-4 PROBODY BMS-986288, a Probody version of the anti-CTLA-4 antibody ipilimumab, will not be further advanced following a recent BMS internal portfolio review.
Lead Product(s): BMS-986288,Nivolumab
Therapeutic Area: Oncology Product Name: BMS-986288
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $2,000.0 million Upfront Cash: $200.0 million
Deal Type: Collaboration March 12, 2024
Details:
CX-2051 is an EpCAM-directed ADC, and CX-801, a dually-masked version of interferon-alpha 2b. Its IND application has been cleared by USFDA for the treatment of EpCAM expressed colorectal cancer.
Lead Product(s): CX-2051
Therapeutic Area: Oncology Product Name: CX-2051
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
The net funding will be used in the development of CX-2029, an investigational a conditionally activated antibody-drug conjugate directed against CD71, the transferrin receptor that is highly expressed on a number of solid and hematologic tumors.
Lead Product(s): CX-2029
Therapeutic Area: Oncology Product Name: CX-2029
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BVF Partners L.P.
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 30, 2023
Details:
The collaboration is to Utilize CytomX’s Novel Probody® Technology Platform for CD3 Bispecific Targets for the treatment of cancer. CytomX and Astellas are also collaborating on additional conditionally activated TCB programs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $1,680.0 million Upfront Cash: $80.0 million
Deal Type: Collaboration January 26, 2023
Details:
Moderna’s global impact has shown the enormous power of mRNA and working closely with the newest collaborator to bring novel, mRNA-based conditionally activated therapeutics to patients with unmet medical needs.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: $1,235.0 million Upfront Cash: $35.0 million
Deal Type: Collaboration January 05, 2023
Details:
Praluzatamab ravtansine (CX-2009) is an investigational conditionally activated ADC directed toward CD166 that has demonstrated single agent clinical activity in a Phase 2 study for patients with advanced HR+/HER2- non-amplified breast cancer.
Lead Product(s): Praluzatamab Ravtansine,Pacmilimab
Therapeutic Area: Oncology Product Name: CX-2009
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
The collaboration is strategically focused on applying CytomX's biologic masking strategies to develop investigational Regeneron bispecific antobodies that remain inactive until activated by proteases in the tumor microenvironment.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals
Deal Size: $2,030.0 million Upfront Cash: $30.0 million
Deal Type: Collaboration November 17, 2022
Details:
BMS-986249 is a conditionally activated CTLA-4-targeting antibody that has shown clinical activity in multiple tumor types, and the safety profile and disease control rate observed in the updated Phase 1 data for BMS-986249 with and without nivolumab is promising.
Lead Product(s): BMS-986249,Nivolumab
Therapeutic Area: Oncology Product Name: BMS-986249
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
